4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

11-K - REVVITY, INC. (0000031791) (Filer)

SD - REVVITY, INC. (0000031791) (Filer)

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

DEFA14A - REVVITY, INC. (0000031791) (Filer)

DEF 14A - REVVITY, INC. (0000031791) (Filer)

S-3ASR - REVVITY, INC. (0000031791) (Filer)

New software further strengthens Revvity's market-leading position in in vivo imaging while empowering scientists with faster, more reproducible insights Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. "Our Living Image Synergy AI software marks a significant leap forward in p

NEW YORK, Sept. 22, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global lab automation market is observing significant growth due to technological advancements, regulatory & quality compliance, and demand for efficiency & throughput. The report runs an in-depth analysis of market trends, key players, and future opportunities. The lab automation market generally comprises a vast array of types, equipment, applications, end users, and geography, which are expected to register strength in the coming years. Check valuable insights in the Lab Automation Market report. You can easily get a sample PDF of the report - https://www.theinsightpartners.com

Combination of Revvity's proprietary Pin-point platform and Profluent's AI-engineered proteins created to inspire accelerated development of novel gene editing therapies Revvity, Inc. (NYSE:RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity's established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit. This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing. Additionally, the Pin-point platform's modular design h

Facility designed to advance the next generation of imaging systems Revvity, Inc. (NYSE:RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will hel

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Bloomberg Indices announced the following changes to the Bloomberg 500 (B500) Index effective prior to the open of trading on Thursday, September 11, to coincide with the semi-annual reconstitution of the index. The B500 contains the 500 most highly capitalized US companies weighted by float market cap, reflecting a market capitalization of $58.19 trillion. Affirm Holdings, Inc. (AFRM), Astera Labs, Inc. (ALAB), The Carlyle Group, Inc. (CG), CyberArk Software, Ltd. (CYBR), EMCOR Group, Inc. (EME), Comfort Systems USA, Inc. (FIX), Insmed,

Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice president, investor relations & ESG Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research Revvity, Inc. (NYSE:RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitiv

Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo

UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

Barclays upgraded Revvity from Equal Weight to Overweight and set a new price target of $140.00 from $125.00 previously

Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $130.00

Leerink Partners initiated coverage of Revvity with a rating of Outperform and set a new price target of $125.00

Jefferies resumed coverage of Revvity with a rating of Hold and set a new price target of $115.00

UBS downgraded Revvity from Buy to Neutral and set a new price target of $125.00 from $105.00 previously

Evercore ISI upgraded Revvity from In-line to Outperform and set a new price target of $125.00 from $88.00 previously

Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $95.00

Facility designed to advance the next generation of imaging systems Revvity, Inc. (NYSE:RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will hel

Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo

Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu

The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec

Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

Fourth quarter revenue of $729 million; 5% reported growth; 6% organic growth Fourth quarter GAAP EPS of $0.78; Adjusted EPS from continuing operations of $1.42 Initiates full year 2025 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $119 million, as compared to $77 million for the same period a year

The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025 to all shareholders of record at the close of business on April 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, dete

Revvity, Inc. (NYSE:RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. Update on Financial Performance The Company is also providing the following preliminary financial results for the fourth quarter 2024: Reported and organic

SC 13G/A - REVVITY, INC. (0000031791) (Subject)

SC 13G/A - REVVITY, INC. (0000031791) (Subject)

SC 13G - REVVITY, INC. (0000031791) (Subject)

SC 13G/A - REVVITY, INC. (0000031791) (Subject)